Related Experiment Video

Updated: Nov 12, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

801

Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis

Yasser Tabana1, Isobel S Okoye2, Arno Siraki1

  • 1Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.

Frontiers in Oncology
|March 22, 2021
PubMed

Insights

Breast cancer research is exploring novel immune targets to overcome limitations of current therapies. Strategies aim to enhance the tumor immune microenvironment for improved breast cancer treatment outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Drug Discovery

Background:

  • Breast cancer presents a significant global health challenge, driving extensive research into novel therapeutic approaches.
  • While immune checkpoint inhibitors show promise, their efficacy in breast cancer is limited by an immunosuppressive tumor microenvironment.
  • Identifying new immunological targets is crucial for modulating this microenvironment and enhancing anti-tumor immunity.

Purpose of the Study:

  • To highlight strategies for increasing breast tumor immunogenicity.
  • To review novel non-classical immune targets for breast cancer therapy.
  • To discuss the preclinical and clinical landscape of these emerging targets.

Main Methods:

  • Literature review of recent studies on breast cancer immunology.
  • Analysis of novel immunological targets and their mechanisms of action.
  • Examination of preclinical and clinical trial data for immunomodulatory agents.

Main Results:

  • Breast cancer is characterized by an inflamed yet immunosuppressive tumor microenvironment.
  • Several novel non-classical immune targets are being investigated to reprogram this microenvironment.
  • These targets aim to enhance immune cell activity against breast cancer.

Conclusions:

  • Targeting novel immunological pathways offers a promising strategy to improve breast cancer immunotherapy.
  • Modulating the tumor immune microenvironment is key to overcoming current treatment limitations.
  • Further research and clinical trials are essential to validate these novel targets for breast cancer treatment.
Keywords:
PD-1PD-L1breast cancerimmune targetsimmunotherapytherapeutic agents

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.0K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
820
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.1K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
610
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
5.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K